From London to the World: How 2026 Put Blue Fin Vision® on the International Ophthalmic Stage
- Posted
- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Mr Mfazo Hove
- Published: September 15, 2026
- Last Updated: September 14, 2026
TL;DR: From invited faculty roles in China, Istanbul and Lausanne to hosting international surgeons in London and moderating a global ZEISS panel during ESCRS, 2026 has marked a step-change in Blue Fin Vision®’s international profile. These engagements have brought international knowledge, clinical discussion and new ideas back into the practice for the benefit of patients.
A Remarkable Week in London
Some weeks tell the story of a year. During the week of the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) at ExCeL London, the diary at Blue Fin Vision® looked like this:
- Wednesday: Blue Fin Vision® hosted a delegation from Rayner’s US commercial team. Five colleagues travelled with the Vice-President for the Americas, having requested a UK clinic co-visit ahead of the launch of the RayOne Galaxy intraocular lens in the United States.
- Thursday: Dinner with the ZEISS practice development team.
- Friday: The ZEISS Beyond event.
- Saturday: Blue Fin Vision® hosted a delegation of 25 doctors visiting from China.
- Sunday: A SpaMedica networking event, followed by Mr Mfazo Hove moderating the international ZEISS intraocular lens (IOL) clinical panel during ESCRS. Faculty were drawn from South Korea, Switzerland, the United Kingdom, China and Spain.
The ZEISS IOL clinical panel during ESCRS London 2026: Sunday 13 September, South Event Hall, Booth C.100.
That week did not happen in isolation. It was the culmination of a year of deliberate international engagement.
It also marked something worth naming plainly: 2026 was the year Blue Fin Vision® moved from being a successful UK surgical practice to becoming a clinic increasingly visible in the international ophthalmic conversation.
China: From Visitor to Invited Faculty
Presenting at the Bridging Horizons, Converging Minds UK-China Summit, Shanghai Aier Eye Hospital Academic Centre, 19 April 2026.
The year’s international programme began in China.
At the ZEISS Horizon Meeting in Shanghai, the ZEISS faculty programme in Hangzhou and a faculty lecture at Aier Eye Hospital in Changsha, Mr Hove was invited to share Blue Fin Vision®’s experience with Chinese colleagues and institutions.
Chinese ophthalmology operates at extraordinary scale, offering a very different perspective on cataract and refractive, or vision-correction, surgery delivery.
The exchange ran in both directions. Discussions covered surgical technique, technology adoption, service design and, above all, the measurement of surgical outcomes.
Presenting Radical Transparency: The Future of Ophthalmic Practice at the ZEISS Horizon 2026 Asia-Pacific (APAC) Ophthalmology Symposium, Shanghai.
The theme that emerged across all three cities was consistent. Blue Fin Vision® was not merely observing international ophthalmology.
Its experience, outcome data and way of thinking about surgical quality were being invited into the discussion.
With fellow international faculty at the ZEISS Horizon 2026 APAC Ophthalmology Symposium, Jing An Shangri-La, Shanghai, 17 to 19 April 2026.
Istanbul: Building the European ZEISS Relationship
Presenting at the ZEISS Europe, Middle East and Africa (EMEA) Cataract and Corneal Refractive User Meeting 2026, Istanbul.
Istanbul continued the same pattern in a European context.
As an invited ZEISS faculty member, meaning a specialist invited to teach and contribute to the professional programme, Mr Hove shared Blue Fin Vision®’s clinical experience with colleagues from across the region. He contributed a UK independent-sector perspective to conversations that are usually dominated by large hospital systems.
What matters here is not the single engagement but the continuity.
The Istanbul meeting sits within an ongoing working relationship with ZEISS, spanning lens technology, diagnostics and surgical platforms. It is built on shared data and honest feedback rather than one-off appearances.
Lausanne: Clinical Science and the Future of the Operating Theatre
The Swiss Ophthalmological Society (SOG-SSO) 119th Annual Congress, Lausanne, Switzerland, August 2026.
The SOG-SSO meeting in Lausanne, with significant ZEISS involvement, looked forward rather than sideways. The programme covered digital microscopes, three-dimensional heads-up operating and technologies likely to reshape the surgical environment over the next decade.
Heads-up three-dimensional visualisation allows the surgeon to operate while viewing a magnified digital display rather than looking through conventional microscope eyepieces. It has been the subject of serious clinical evaluation for a decade, with early published work demonstrating both its feasibility and ergonomic advantages for the operating surgeon.¹
For Blue Fin Vision®, meetings like Lausanne serve a specific purpose.
The practice’s standing decision framework is to adopt technology early only where patients pull demand and the clinical effect is verifiable at the bedside. It declines where vendors push and the endpoint is obscured.
That discipline is only possible if you are in the room where new technology is being debated by the people building and testing it.
London: The World Comes to Blue Fin Vision®
The most significant shift of 2026, however, was not where Blue Fin Vision® travelled. It was who travelled to Blue Fin Vision®.
Throughout the year, international surgeons and delegations visited the practice. These visits culminated in the 25-doctor Chinese delegation hosted during ESCRS week itself.
Industry made the same choice. When Rayner’s US team crossed the Atlantic for ESCRS and asked which UK clinics to visit ahead of the RayOne Galaxy’s American launch, Blue Fin Vision® was on the itinerary.
Visiting colleagues came to see how a consultant-led independent practice organises its surgical pathways, measures its outcomes and communicates with its patients.
The ZEISS IOL panel during ESCRS distilled the same idea into a single hour. Its faculty included surgeons from South Korea, Switzerland, the United Kingdom, China and Spain.
They compared published evidence and personal experience across three types of lens platform. Trifocal lenses provide focal points for near, intermediate and distance vision. Extended depth of focus lenses extend the range of clear vision, while monofocal lenses provide one principal point of focus.
The discussion included long-term six-year follow-up data.²
The direction of travel is the point. A practice begins by going abroad to learn and share. It matures when international colleagues start coming to it.
What Was Happening Clinically at Home
None of this would matter if it were detached from the day job. In 2026, the practice was also deepening its clinical work at home.
Mr Hove passed 57,000 procedures across his surgical career and published his sixth consecutive year of National Ophthalmology Database outcome data. The National Ophthalmology Database is the national audit framework that has defined transparent cataract surgery benchmarking in the UK since its landmark first report.³
His latest NOD-format audit, structured according to National Ophthalmology Database reporting standards, covered approximately 5,600 cataract operations. The posterior capsule, the thin membrane that supports the lens implant, was preserved in approximately 99.8% of eyes.
The practice continued to develop its cataract, refractive, Implantable Collamer Lens (ICL) and vitreoretinal services. Vitreoretinal care covers conditions affecting the retina and the clear vitreous gel inside the eye.
The dropless cataract pathway progressed, while infection prevention remained underpinned by evidence-based perioperative prophylaxis, meaning preventive medication given around the time of surgery.⁴
Across approximately 36,000 consecutive cataract and lens replacement procedures over approximately six years, Blue Fin Vision® has recorded zero cases of endophthalmitis, a rare but serious infection inside the eye.
The Lifetime Monitoring Protocol™ was formalised as a service commitment for ICL patients. It reflects published long-term evidence that phakic lens outcomes remain excellent over many years but deserve structured surveillance rather than discharge and hope. A phakic lens is an implanted lens that works alongside the eye’s natural lens.⁵
Seven-day emergency retinal capability, under Consultant Vitreoretinal Surgeon Professor Mahmut Dogramaci, matured alongside continued investment in diagnostics, outcomes measurement and patient education.
The practice’s educational work with trainees and surgical video also continued to grow.
Presenting at the Royal College of Ophthalmologists Annual Congress 2026, Manchester.
Building an Institution, Not a Personal Profile
It would be easy to read this year as a story about invitations. It is really a story about infrastructure.
The objective has never been simply for Mr Hove to be invited to more meetings.
Every faculty invitation, visiting delegation, industry relationship and research conversation increases the volume of knowledge flowing back into Blue Fin Vision®. It informs the practice’s protocols, technology decisions, consent conversations and outcome measurement.
Increasingly, visiting delegations are coming not simply to meet an individual surgeon, but to understand the system around him.
That system rests on the principle that has anchored the Blue Fin Vision® Doctrine from the beginning: to achieve the immeasurable, you must measure everything.
The Beginning, Not the Victory Lap
China. Istanbul. Lausanne. London.
With several months of 2026 still to run, the direction is already clear.
International profile is valuable only if it improves clinical thinking and, through it, patient care. The test of this year is not the photographs. It is whether patients at Blue Fin Vision® are counselled better, measured better and treated better because of what was learnt in four countries.
The goals ahead are already set: deepen the collaborations begun this year, expand the educational work, grow the research and outcomes programme, and continue the international exchange.
This is the beginning of the story, not the end of it.
Disclosure: Mr Mfazo Hove is a ZEISS Key Opinion Leader and works with a number of ophthalmic industry partners. Blue Fin Vision® technology and lens decisions are based on clinical evidence and individual patient suitability and are not restricted to any single manufacturer.
References
- Eckardt C, Paulo EB. Heads-up surgery for vitreoretinal procedures: an experimental and clinical study. Retina. 2016;36(1):137-147.
- Fernández J, Rodríguez-Vallejo M, Martínez J, Burguera N, Piñero DP. Long-term efficacy, visual performance and patient reported outcomes with a trifocal intraocular lens: a six-year follow-up. J Clin Med. 2021;10(9):2009.
- Day AC, Donachie PHJ, Sparrow JM, Johnston RL. The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 1, visual outcomes and complications. Eye (Lond). 2015;29(4):552-560.
- Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology. 2017;124(6):768-775.
- Igarashi A, Shimizu K, Kamiya K. Eight-year follow-up of posterior chamber phakic intraocular lens implantation for moderate to high myopia. Am J Ophthalmol. 2014;157(3):532-539.
ABOUT THE AUTHOR
Mr Mfazo Hove
Consultant Ophthalmic Surgeon
MBChB MD FRCOphth CertLRS
Mr Mfazo Hove is a Consultant Ophthalmic Surgeon with experience spanning more than 57,000 procedures. He completed 6.5 years of specialist training at Moorfields Eye Hospital and served for five years as a consultant at the Western Eye Hospital, Imperial College Healthcare NHS Trust. He is the founder of Blue Fin Vision®, a consultant-led private ophthalmology practice operating across London, Essex, and Hertfordshire. His clinical expertise encompasses advanced cataract surgery, refractive lens replacement, laser vision correction, and implantable Collamer lenses (ICL).
A ZEISS Key Opinion Leader, Mr Hove is a respected international speaker with five invited engagements across seven cities in 2026:
- ZEISS China tour (Changsha, Shanghai, and Hangzhou, April – ZEISS APAC User Meeting)
- RCOphth Annual Congress – May – Manchester
- ZEISS EMEA User Meeting (Istanbul)
- ZEISS Lausanne User Meeting (Lausanne)
- European Society of Cataract and Refractive Surgeons Annual Congress (ESCRS, London)
